Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors
ChemMedChem · 2026
DOI: 10.1002/cmdc.70459 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Yixuan Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditio…. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Design, SARS-CoV-2, Coronavirus 3C Proteases. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai PuJiang Programme.
Abstract (Originalsprache)
The SARS‐CoV‐2 3C‐like protease (3CL pro ) is an essential enzyme for coronavirus replication and remains an attractive antiviral target due to its high sequence conservation among coronaviruses. Based on a previously identified catechol‐containing covalent 3CL pro inhibitor ( P1‐E11 ), structural optimization was carried out using a linker‐replacement strategy to systematically modify the central linker moiety. Two series comprising 20 analogues were designed, synthesized, and evaluated for enzymatic and antiviral activities. Among them, compound B2 , featuring a direct amide linkage between the catechol warhead and the 4‐(trifluoromethoxy)phenyl group, exhibited improved enzymatic inhibition (IC 50 = 0.83 ± 0.06 μM) and favorable covalent inhibition kinetics ( k inact / K i = 380.01 M −1 s −1 ). In cell‐based assays (A549‐hACE2‐TMPRSS2), B2 showed antiviral activity (EC 50 = 15.03 ± 1.13 μM) with acceptable cytotoxicity (CC 50 = 79.87 ± 6.85 μM). Structure–activity relationship analysis revealed that sulfur‐containing linkers enhanced antiviral potency in certain cases but were associated with increased cytotoxicity. Collectively, this study expands the structural framework of covalent 3CL pro inhibitors and offers a rational strategy for their further optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medic…
- Phase I Clinical Trials Center, Shenzhen People's Hospital (The First Affiliated Hospital Southern University of Science and Technology; The Second Clinical Medical College Jinan University), Shenzhen, China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, Guangdong, China.
- Health and Quarantine Laboratory, Guangzhou Customs District Technology Center, Guangzhou, China.
ORCID-Profile: Wenhao Zhao, Ping Tian, Dingding Gao
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai PuJiang Programme
- Shanghai Leading Talent Program of Eastern Talent
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine
- Shanghai Municipal Health Commission
- Expenditure Budget Program of Shanghai University of Traditional Chinese Medicine
- Shanghai Frontiers Science Center for Traditional Chinese Medicine Chemical Biology, and Guangdong High-Level Talent Program
Zitieren
APA
Feng, Y., Wang, F., Liu, D., Yan, Q., Kang, L., Zhao, W., Jin, S., Huang, S., Zhao, J., Tian, P., & Gao, D. (2026). Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.70459
Vancouver
Feng Y, Wang F, Liu D, Yan Q, Kang L, Zhao W, et al. Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors. ChemMedChem. 2026. doi:10.1002/cmdc.70459
BibTeX
@article{Feng2026,
author = {Feng, Yixuan and Wang, Feng and Liu, Donglan and Yan, Qiqi and Kang, Leyuan and Zhao, Wenhao and Jin, Shixin and Huang, Shuxiang and Zhao, Jincun and Tian, Ping and Gao, Dingding},
title = {Design, Synthesis, and Structure–Activity Relationship Studies of Novel 3CL pro Inhibitors},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70459}
}
EUVIMED